Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06192004 · ClinicalTrials.gov registry record
Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD
A clinical trial, sponsored by AstraZeneca.
- Terminated
- Registry status
- 83
- Enrollment target
NCT06192004: Clinical Trial study, sponsored by AstraZeneca.
NCT06192004 is a clinical trial that was terminated before completion, run by AstraZeneca. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06192004 was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- 83 participants
- Enrollment target
Study Summary
This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution. Patients initiating treatment for non-small cell lung cancer (NSCLC) will be prospectively followed to characterize risk factors, signs, and symptoms leading to onset, diagnosis, and treatment of pneumonitis/ILD should it occur.
Primary Outcome
To complement the development of the algorithm to identify a patient at risk of pneumonitis/ILD.
Interventions
- OTHER None (Observational Study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2024-01-05 |
| Est. Completion | 2025-04-30 |
Why NCT06192004 stopped before completion
NCT06192004 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 83 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which None (Observational Study) is the first listed.
NCT06192004 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06192004 about?
NCT06192004 is a clinical study titled "Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD". This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution. Patients initiating treatment for non-small cell lung cancer (NSCLC) will be prospectively followed to characterize risk...
What is the current status of trial NCT06192004?
This trial is currently terminated. The enrollment target is 83 participants. The study started on 2024-01-05. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT06192004?
The interventions under investigation include: None (Observational Study) (OTHER).
Who is sponsoring clinical trial NCT06192004?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI